Generated November 12, 2026 at 8:34 PM ET
· Covers November 12 trading day
· 7 of 528 ready 8-Ks selected
· AI-assisted overview
The day's most material 8-K was NVIDIA's disclosure that Jensen Huang resigned as president, CEO and director effective November 11, 2026, with CFO Colette Kress named interim CEO and director Harvey Jones appointed first-ever board chair. Two exchange-listing actions were also reported: SHF Holdings said Nasdaq will delist it and suspend trading November 18 after ten days at or below $0.10, and AtlasClear said NYSE American suspended trading November 10 and began delisting proceedings over low share price, with shares expected on OTC Pink. Three transactions were covered: Rallybio set a November 20 close for its Avenzo merger with a $13.90 per share cash distribution, Sempra closed its sale of 45% of Sempra Infrastructure to KKR and CPPIB for $4.56 billion in cash plus notes, and Integral Technologies acquired 80% of the Apex North critical minerals project in a $27.3 million reverse merger. InspireMD also reported FDA approval of its CGuard Prime TCAR stent system, which it said doubles its US addressable market.
leadership
negative
materiality 1.00
November 12, 2026, 8:52 AM ET
Jensen Huang resigns as NVIDIA CEO; CFO Colette Kress named interim CEO, Harvey Jones board chair
- Board accepted Huang's resignation as President, CEO and director effective November 11, 2026; he co-founded NVIDIA and led it 33 years.
- Colette Kress, EVP and CFO since September 2013, serves as interim CEO and keeps CFO duties while board searches internal and external candidates.
- Harvey C. Jones, director since 1993 and former Synopsys CEO/Executive Chairman, appointed NVIDIA's first-ever Chair of the Board.
regulatory
negative
materiality 0.95
November 12, 2026, 5:28 PM ET
Nasdaq to delist SHF Holdings; trading suspended Nov 18 after 10 days at or below $0.10
- Nasdaq said SHFS closed at $0.10 or less for 10 consecutive trading days from Oct 28 to Nov 10, 2026; trading suspends at open Nov 18 and Nasdaq will file Form 25-NSE.
- SHF may appeal to Nasdaq Hearings Panel, but a timely hearing request will not stay the suspension; it is considering a reverse stock split and still intends to close the Opifex Media deal.
- From Oct 30 through Nov 11, 2026, SHF issued 63,247,931 shares upon conversion of 7,730 Series B preferred at $0.1210/share, receiving no additional consideration.
ATCH
AtlasClear Holdings, Inc.
regulatory
negative
materiality 0.90
November 12, 2026, 6:06 AM ET
NYSE American suspends AtlasClear trading, starts delisting over low share price; ATCH to OTC
- NYSE American suspended trading in AtlasClear (ATCH) on Nov 10, 2026 and began delisting proceedings under Section 1003(f)(v) over the stock's low selling price.
- AtlasClear intends to appeal to a Listing Qualifications Panel and may pursue a reverse stock split; shares are expected to quote on the OTC Pink Limited Market under ATCH from Nov 11, 2026.
- AtlasClearing remains compliant with regulatory net capital requirements and has signed eight correspondent broker-dealer agreements; onboarding continues.
M&A
positive
materiality 0.85
November 12, 2026, 4:41 PM ET
Rallybio expects Avenzo merger to close Nov 20; sets $13.90/share cash distribution
- Avenzo Therapeutics merger under May 31, 2026 agreement expected to close after market close Nov 20, 2026; Nasdaq approved listing of common stock for the deal.
- Special cash distribution of $13.90/share to holders of record Nov 5, 2026; deposit with transfer agent Nov 19, payments expected to begin Nov 30, 2026.
- Nasdaq due-bill period runs from Nov 5 record date through close on Nov 20; buyers in that period receive the cash distribution, while sellers do not.
M&A
positive
materiality 0.85
November 12, 2026, 4:16 PM ET
Sempra closes sale of 45% of Sempra Infrastructure to KKR/CPPIB; $4.56B cash, $2.8-3.3B gain
- Received $4.56B cash at closing; remainder via $4.14B note at 7.5% due Dec 31, 2027 ($4.51B with interest) and $1.20B note at 8.5%/10.0% due Feb 11, 2034 ($2.31B).
- Expects pre-tax gain on sale of $2.80B-$3.30B ($2.00B-$2.40B after tax) plus $450M-$550M of additional transaction costs ($325M-$400M after tax).
- Post-close ownership: KKR Partners 65%, Sempra 25%, ADIA 10%; SI Partners deconsolidated Nov 12, 2026 and now equity-method within the Sempra Infrastructure segment.
regulatory
positive
materiality 0.80
November 12, 2026, 4:45 PM ET
InspireMD wins FDA approval for CGuard Prime TCAR stent, doubling US addressable market
- FDA approved the PMA supplement for the CGuard Prime TransCarotid Stent System (80 cm delivery) for TCAR procedures used with an embolic protection system specified in labeling.
- Approval adds access to more than 35,000 annual US TCAR procedures, doubling CGuard Prime's TAM; TCAR plus CAS total ~75,000 US carotid stenting procedures yearly per company estimates.
- CGUARDIANS II pivotal trial: 50 patients across 11 US sites; 100% acute device success with zero death, stroke, MI or stent thrombosis at 30 days.
—
INTEGRAL TECHNOLOGIES INC
M&A
positive
materiality 0.80
November 12, 2026, 3:43 PM ET
Integral Technologies buys 80% of Apex North critical minerals project in $27.3M reverse merger
- Acquired 80% of Apex North LLC from Dragonstone Metals Ltd. and Nedeel LLC for 390,714 Series D preferred shares with $27,349,980 stated value, convertible at $0.07.
- Series D represented ~85.91% of total voting power at closing, effecting a change of control; Green Iguana and Kryptonite retain 20% with a free carry.
- Apex North holds ~394 unpatented lode claims covering ~3,294 hectares (8,141 acres) in Washington County, Utah; no Proven or Probable Reserves.